QuickView for Fluphenazine (compound)

Summary
General Info

PubChem

PubChem Compound 3372

Name:	Fluphenazine
PubChem Compound ID:	3372
Description:	A phenothiazine used in the treatment of PSYCHOSES. Its properties and uses are generally similar to those of CHLORPROMAZINE.
Molecular formula:	C₂₂H₂₆F₃N₃OS
Molecular weight:	437.523 g/mol
Synonyms:	Fluphenazine hydrochloride; 4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol; 4-[3-(2-Trifluoromethyl-10-phenothiazyl)-propyl]-1-piperazineethanol; 1-Piperazineethanol, 4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-, dihydrochloride; Lyorodin; Siqualon; Prestwick1_000320; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9CI); Prestwick0_000320; KBio1_000511. show more » Fluphenazine hydrochloride; 4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol; 4-[3-(2-Trifluoromethyl-10-phenothiazyl)-propyl]-1-piperazineethanol; 1-Piperazineethanol, 4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-, dihydrochloride; Lyorodin; Siqualon; Prestwick1_000320; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9CI); Prestwick0_000320; KBio1_000511; Fluphenazine dihydrochloride; Fluorophenazine dihydrochloride; Spectrum_000289; 1-Piperazineethanol, 4-[3-[2- (trifluoromethyl)phenothiazin-10-yl]propyl]-, dihydrochloride; 69-23-8; KBio2_004954; Anatensol; Squibb 4918; C07010; OMCA; Calmansial; A 4077; 1-(2-Hydroxyethyl)-4-[3-(trifluoromethyl-10-phenothiazinyl)propyl]piperazine; KBioSS_002391; Fluorfenazine; NSC179197; Tensofin; Siqualine; Sevinol; Pacinol; Moditen; 10-(3'-(4-(beta-Hydroxyethyl)-1-piperazinyl)-propyl)-3-trifluoromethylphenothiazine; Fluorphenazine; KBio2_000769; S94; Lopac-F-4765; KBioGR_002386; Fluphenazine; KBioGR_001375; 146-56-5; Liogen; KBio2_002386; KBio3_002320; KBioSS_000769; 1-Piperazineethanol, 4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-; Dapotum; NSC62323; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-; 4-(3-(-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; NSC 62323; Phenothiazine, 10-(3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl)-2-(trifluoromethyl)-; Fluorophenazine; NCGC00015436-01; NCGC00015436-02; 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-Piperazineethanol; 10-[3-[4-(2-Hydroxyethyl)piperazinyl]propyl]-2-trifluoromethylphen othiazine dihydrochloride; CAS-146-56-5; Fluphenazinum [INN-Latin]; AIDS-015551; KBio2_005905; Flufenazin; 1-(2-Hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine; Flufenazina [DCIT]; Spectrum2_001199; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; 2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-pipe razinyl)propyl)phenothiazine; SPBio_001277; KBio2_007522; SQ 4918; 4-(3-(2-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; HSDB 3334; Triflumethazine; 1-Piperazineethanol, 4-[3-[2- (trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-, dihydrochloride; Ftorphenazine; 4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazineet hanol, dihydrochloride; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-; Prolixin; DivK1c_000511; AIDS015551; Elinol; Phthorphenazine; Spectrum3_001420; KBio2_003337; Permitil; KBio3_002865; EINECS 200-702-9; Vespazine; SPBio_002539; Fluphenazine chloride; NINDS_000511; Valamina; ChemDiv1_024180; Spectrum4_000828; Moditen (Tabl or elixir); 47646-09-3 show less «

DrugBank

Identification

Name:	Fluphenazine
Name (isomeric):	DB00623
Drug Type:	small molecule
Description:	A phenothiazine used in the treatment of PSYCHOSES. Its properties and uses are generally similar to those of CHLORPROMAZINE.
Synonyms:	Fluorophenazine; Fluorfenazine; Fluorphenazine; Triflumethazine; Fluphenazine Decanoate; Fluphenazine Hcl
Brand:	Prolixin Concentrate, Yespazine, Siqualine, Apo-Fluphenazine, Moditen Enanthate, Permitil Concentrate, Prolixin Enanthate, Siqualon, Elinol, Vespazine, Prolixine, Modecate, Prolixin, Sevinol, Moditen Hcl
Category:	Phenothiazines, Dopamine Antagonists, Antipsychotic Agents, Antipsychotics
CAS number:	69-23-8

Pharmacology

Indication:	For management of manifestations of psychotic disorders.
Pharmacology:	Fluphenazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Fluphenazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.
Mechanism of Action:	Fluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Avoid alcohol.

Take with food to reduce irritation.

Drug interaction:

Grepafloxacin	Increased risk of cardiotoxicity and arrhythmias
Levofloxacin	Increased risk of cardiotoxicity and arrhythmias
Amphetamine	Decreased anorexic effect, may increase psychotic symptoms
Metrizamide	Increased risk of convulsions
Sparfloxacin	Increased risk of cardiotoxicity and arrhythmias

Grepafloxacin	Increased risk of cardiotoxicity and arrhythmias
Levofloxacin	Increased risk of cardiotoxicity and arrhythmias
Amphetamine	Decreased anorexic effect, may increase psychotic symptoms
Metrizamide	Increased risk of convulsions
Sparfloxacin	Increased risk of cardiotoxicity and arrhythmias
Triprolidine	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Fluphenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
Tetrabenazine	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
Tacrine	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Fluphenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
Phentermine	Decreased anorexic effect, may increase psychotic symptoms
Phenylpropanolamine	Decreased anorexic effect, may increase psychotic symptoms
Bromocriptine	The phenothiazine decreases the effect of bromocriptine
Trospium	Trospium and Fluphenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Terbinafine	Terbinafine may reduce the metabolism and clearance of Fluphenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluphenazine if Terbinafine is initiated, discontinued or dose changed.
Trimethobenzamide	Trimethobenzamide and Fluphenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Dextroamphetamine	Decreased anorexic effect, may increase psychotic symptoms
Methamphetamine	Decreased anorexic effect, may increase psychotic symptoms
Mazindol	Decreased anorexic effect, may increase psychotic symptoms
Benzphetamine	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
Terfenadine	Increased risk of cardiotoxicity and arrhythmias
Phendimetrazine	Decreased anorexic effect, may increase psychotic symptoms
Atomoxetine	Risk of additive CNS depressant effects. Monitor for increased CNS depression during concomitant therapy.
Fenfluramine	Decreased anorexic effect, may increase psychotic symptoms
Guanethidine	Fluphenazine may decrease the effect of guanethidine.
Gatifloxacin	Increased risk of cardiotoxicity and arrhythmias
Phenmetrazine	Decreased anorexic effect, may increase psychotic symptoms
Cisapride	Increased risk of cardiotoxicity and arrhythmias
Diethylpropion	Decreased anorexic effect, may increase psychotic symptoms
Dexfenfluramine	Decreased anorexic effect, may increase psychotic symptoms

show less «

Targets

D(2) dopamine receptor

D(1A) dopamine receptor

Enzymes

Transporters

Multidrug resistance protein 1